Take­da ex­plores com­pu­ta­tion­al chem­istry leads from Schrödinger in $170M-plus pact; Aeter­na Zen­taris boots CEO, con­sid­ers op­tions

→ Take­da is in­clud­ing an in sil­i­co dis­cov­ery pact with Schrödinger to aug­ment its re­struc­tured R&D op­er­a­tions. Schrödinger stands to earn up to $170 mil­lion per pro­gram in the deal, look­ing to de­sign new chem­i­cal en­ti­ties that the phar­ma com­pa­ny can take in­to the clin­ic. “In this case, Schrödinger is tak­ing the lead role in dis­cov­ery, with Take­da play­ing a sup­port­ing role, lever­ag­ing its in-house struc­tur­al bi­ol­o­gy team and ther­a­peu­tic area ex­per­tise,” says Take­da’s Stephen Hitch­cock.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER